南京美瑞制药有限公司

What 南京美瑞制药有限公司 does

南京美瑞制药有限公司 (Nanjing Meirui Pharmaceutical Co., Ltd.) is registered in Nanjing, Jiangsu province, China, with a stated headcount of 7 employees. Its listed website URL (https://www.gsk-china.com/) is the corporate site of GSK China (葛兰素史克), suggesting either an authorized distribution, sales agency, or affiliated commercial relationship with GSK's China operations. The aggregated source data contains no first-party information specific to this entity — no disclosed revenue, no product list, no company history, no ownership or parent-company mapping, no management team, and no funding record. Every substantive data point in the input (extensive product portfolio in vaccines, specialty, and general medicines; multiple 2025–2026 NMPA approvals including Trelegy, Blenrep, and depemokimab; a 2026 strategic collaboration with China Biologics covering 9,000+ hospitals; R&D focus across respiratory, immunology, oncology, HIV, and infectious disease) pertains to GSK China group entities, not to 南京美瑞制药有限公司 itself. As a result, the entity's actual operational scope, business model, revenue mechanics, and customer base cannot be characterized from the available evidence.

Name

南京美瑞制药有限公司

Legal name

No legal name for 南京美瑞制药有限公司 found in the provided source data. Source material is exclusively about GSK (葛兰素史克) China entities.

Website

https://gsk-china.com

Company type

Private

Headcount range

1–10 employees

Short description

Nanjing Meirui Pharmaceutical Co., Ltd. (南京美瑞制药有限公司) is a 7-employee, Nanjing-based pharmaceutical entity whose registered website URL points to GSK China, suggesting a small-scale commercial or distribution affiliation with GSK's China operations. No first-party operating data is available.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Adult Vaccines (HLAIAEAB)

akta.pro secondary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Vaccines and biologics
• Specialty pharmaceuticals
• Respiratory medicines
• Oncology therapeutics
• HIV treatments

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Core offering

GSK China develops, registers, and commercializes innovative vaccines, specialty biologics, and general medicines across four therapeutic areas: respiratory/immunology/inflammation, oncology, HIV, and infectious diseases. The product portfolio includes recombinant vaccines (Shingrix, Cervarix, Engerix-B, RSV candidate), anti-IL-5 biologics (Nucala, depemokimab), BCMA-targeted ADCs (Blenrep), long-acting HIV injectables (Vocabria/Rekebo), and inhaled triple therapies (Trelegy). Products are marketed to hospitals, primary care institutions, and healthcare professionals across China.

Product overview

葛兰素史克(GSK)是一家全球生物医药公司，产品组合涵盖三大领域：疫苗、特药和普药。疫苗产品包括欣安立适(重组带状疱疹疫苗)、希瑞适(双价HPV疫苗)和安在时(重组乙型肝炎疫苗)。特药产品包括新可来(美泊利珠单抗)、万凯锐(卡替拉韦)、倍乐锐(注射用玛贝兰妥单抗)、倍力腾(贝利尤单抗)、易适来(德莫奇单抗)等创新生物制剂和抗病毒药物。普药产品包括全再乐(氟替美维)、欧乐欣(乌美溴铵维兰特罗)、舒利迭、辅舒酮、万托林等呼吸系统药物，以及多伟托、特威凯、绥美凯等HIV治疗药物。公司优先投入疫苗和特药研发，聚焦呼吸、免疫及炎症、肿瘤、HIV及感染性疾病四大治疗领域。

Differentiator

Problem solved

Functional benefit

Products and services

• 新可来 (Nucala/mepolizumab)

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Novartis (China): Novartis operates in specialty pharma, respiratory and oncology in China with comparable hospital-facing biologics; an obvious peer for a multinational vaccines/biologics franchise.
• Sanofi (China): Sanofi competes in adult vaccines (flu, travel), specialty care (Dupixent in asthma/CRSwNP) and rare disease — direct overlap with GSK's vaccine business and the IL-5/IL-4/5R pathway in eosinophilic respiratory disease.
• AbbVie (China): AbbVie is a leading immunology peer (Humira/Skyrizi/Rinvoq) and competes in hematologic and immunologic indications that overlap with Benlysta, Blenrep and depemokimab's specialty franchises.
• Pfizer (China): Pfizer competes across vaccines (Prevnar), oncology and antivirals in China with comparable large-pharma commercial reach, and overlaps directly with GSK's vaccine franchise and biologics pipeline.
• Gilead Sciences (China): Gilead is the dominant HIV peer (Biktarvy, lenacaprav-based long-acting regimens) competing directly with Vocabria/Rekebo and Dovato/Tivicay/Triumeq in China's HIV treatment landscape.
• Merck & Co. (MSD China): MSD competes head-to-head with Gardasil (HPV) versus Cervarix, Keytruda in oncology versus Blenrep, and has a parallel large-vaccine and immuno-oncology presence in China.
• Johnson & Johnson Innovative Medicine (China): Janssen competes in oncology (multiple myeloma, haematology), immunology and vaccines in China, with overlapping specialty/biologic capabilities and similar hospital-channel dynamics.
• Bristol-Myers Squibb (China): BMS is a key oncology and HIV peer (Revlimid/Pomalyst in multiple myeloma, HIV portfolio) with direct overlap to Blenrep and the Vocabria/Rekebo long-acting HIV regimen.
• AstraZeneca (China): AstraZeneca is the most direct respiratory peer with Symbicort, Breztri Aerosphere and Fasenra/Tezspire competing head-to-head against Trelegy, Anoro, Seretide, Nucala and depemokimab in China; both companies lead the Chinese inhaled/biologic respiratory market.
• Roche (China): Roche is a major oncology and immunology peer in China with overlapping biologics capabilities (haematology, immunology) and competing launches in similar hospital channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/%E5%8D%97%E4%BA%AC%E7%BE%8E%E7%91%9E%E5%88%B6%E8%8D%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 南京美瑞制药有限公司